Tüdőrák: nyitott vizsgálatok itt: Ausztria
58 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Krems An Der Donau, Vienna, Wels
- Age
- 18 év and over
- People
- 1000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386EU 2024-513682-40-01Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Feldkirch, Innsbruck, Krems An Der Donau, Linz
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170EU 2025-524263-21-01Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Eisenstadt, Graz, Klagenfurt Am Woerthersee, Krems An Der Donau, Vienna, Wels
- Age
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356EU 2022-501863-41-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
- Where
- Vienna
- Age
- 18 év and over
- People
- 290 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06284317EU 2023-508773-82-00Regiszter frissítve: 2026-11-06
No phaseToborozResearch participation
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- Where
- Krems, Linz, Vienna, Wels
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07284121Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Innsbruck, Linz, Vienna
- Age
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497EU 2025-523576-23-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Feldkirch, Linz, Vienna
- Age
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581EU 2023-503412-33-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Salzburg, Vienna
- Age
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277EU 2024-511319-91-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Graz, Linz, Vienna
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598EU 2024-512302-25-00Regiszter frissítve: 2026-11-04
3. fázisToborozResearch participation
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
- Where
- Linz, Salzburg
- Age
- 18 év and over
- People
- 65 worldwide
- Run by
- Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00EU 2022-502959-54-00Regiszter frissítve: 2026-11-03
4. fázisToborozTrial-stage medicine
Dabrafenib and/or Trametinib Rollover Study
- Where
- Innsbruck
- Age
- 18 év to 100 év
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506EU 2023-509318-13-00Regiszter frissítve: 2026-11-03
No phaseToborozResearch participation
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
- Where
- Graz, Klagenfurt, Natters
- Age
- 18 év and over
- People
- 380 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07230691Regiszter frissítve: 2026-11-03
2/3. fázisToborozTrial-stage medicine
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Linz, Vienna
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319EU 2025-525013-23-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Innsbruck, Vienna
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695EU 2025-521284-12-00Regiszter frissítve: 2026-11-02
2/3. fázisToborozTrial-stage medicine
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Krems An Der Donau, Linz, Vienna
- Age
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596EU 2023-508922-83-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Feldkirch, Innsbruck, Linz, Salzburg, Vienna, Wels
- Age
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846EU 2023-505749-14-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Linz, Vienna
- Age
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143EU 2023-510128-66-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Feldkirch, Innsbruck, Krems An Der Donau, Vienna
- Age
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738EU 2024-514281-39-00Regiszter frissítve: 2026-10-29
1. fázisToborozTrial-stage medicine
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Linz
- Age
- 18 év and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804EU 2024-511246-39-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Feldkirch, Innsbruck, Krems An Der Donau, Linz, Vienna, Wels
- Age
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533EU 2023-505077-32-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Where
- Vienna
- Age
- 18 év and over
- People
- 390 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717EU 2024-519901-36-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Linz, Vienna
- Age
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517EU 2025-520565-51-00Regiszter frissítve: 2026-10-28
1/2. fázisToborozTrial-stage medicine
A Study of DS-3939a in Participants With Solid Tumors
- Where
- Innsbruck, Vienna
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07739966EU 2026-525218-75-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Graz, Linz, Vienna, Wels
- Age
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310EU 2024-515698-85-00Regiszter frissítve: 2026-10-27
3. fázisToborozTrial-stage medicine
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Graz, Vienna
- Age
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729EU 2023-507776-42-00Regiszter frissítve: 2026-10-26
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.